The side effects of the prostaglandin analogues

Bibliography

• EUROPEAN GLAUCOMA SOCIETY: Terminology and guidelines for glaucoma (2nd edition). DOGMA S.r.l., Savona, Canada (2003).
   Google Scholar
• ALM A: Prostaglandin derivates as ocular hypotensive agents. Prog. Retin. Eye Res. (1998) 17(3):291-312.
   PubMed Web of Science ®Google Scholar
• EISENBERG DL, CAMRAS CB: A preliminary risk–benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension. Drug Saf. (1999) 20(6):505-514.
   PubMed Web of Science ®Google Scholar
• WHITSON JT: Travoprost – a new prostaglandin analogue for the treatment of glaucoma. Expert Opin. Pharmacother. (2002) 3(7):965-977.
   PubMedGoogle Scholar
• EISENBERG DL, TORIS CB, CAMRAS CB: Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv. Ophthalmol. (2002) 47(Suppl. 1):S105-S115.
   PubMed Web of Science ®Google Scholar
• EASTHOPE SE, PERRY CM: Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging (2002) 19(3):231-248.
   PubMed Web of Science ®Google Scholar
• CANTOR LB: Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Expert Opin. Investig. Drugs (2001) 10(4):721-731.
   PubMed Web of Science ®Google Scholar
• CAMRAS CB, TORIS CB, SJOQUIST B et al.: Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology (2004) 111(12):2193-2198.
   PubMed Web of Science ®Google Scholar
• OTA T, AIHARA M, NARUMIYA S, ARAIE M: The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest. Ophthalmol. Vis. Sci. (2005) 46(11):4159-4163.
   PubMed Web of Science ®Google Scholar
• MELLO PAA, YANNOULIS NC, HAQUE RM: Safety of unoprostone isopropyl as mono- or adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension. Drug Saf. (2002) 25(8):538-597.
   Google Scholar
• JOHNSTONE MA: Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am. J. Ophthalmol. (1997) 124(4):544-547.
   PubMed Web of Science ®Google Scholar
• HART J, SHAFRANOV G: Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost. Am. J. Ophthalmol. (2004) 37(4):756-757.
   Google Scholar
• SUGIMOTO M, SUGIMOTO M, UJI Y: Quantitative analysis of eyelash lengthening following topical latanoprost therapy. Can. J. Ophthalmol. (2002) 37(6):342-345.
   PubMed Web of Science ®Google Scholar
• PARRISH RK, PALMBERG P, SHEU WP; XLT STUDY GROUP: A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am. J. Ophthalmol. (2003) 135(5):688-703.
   PubMed Web of Science ®Google Scholar
• ALM A, SCHOENFELDER J, MCDERMOTT J: A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch. Ophthalmol. (2004) 122(7):957-965.
   PubMed Web of Science ®Google Scholar
• NETLAND PA, LANDRY T, SULLIVAN EK et al.: Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. (2001) 132(4):472-484.
   PubMed Web of Science ®Google Scholar
• GOLDBERG I, CUNHA-VAZ J, JAKOBSEN JE, NORDMANN JP, TROST E, SULLIVAN EK; INTERNATIONAL TRAVOPROST STUDY GROUP: Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J. Glaucoma (2001) 10(5):414-422.
   PubMed Web of Science ®Google Scholar
• BRANDT JD, VANDENBURGH AM, CHEN K, WHITCUP SM; BIMATOPROST STUDY GROUP: Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology (2001) 108(6):1023-1031.
   PubMed Web of Science ®Google Scholar
• SHERWOOD M, BRANDT J; BIMATOPROST STUDY GROUPS 1 AND 2: Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv. Ophthalmol. (2001) 45(Suppl. 4):S361-S368.
   Web of Science ®Google Scholar
• NOECKER RS, DIRKS MS, CHOPLIN NT, BERNSTEIN P, BATOOSINGH AL, WHITCUP SM; BIMATOPROST/LATANOPROST STUDY GROUP: A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am. J. Ophthalmol. (2003) 135(1):55-63.
   PubMed Web of Science ®Google Scholar
• UNO H, ZIMBRIC ML, ALBERT DM, STJERNSCHANTZ J: Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: a pilot study. Acta Derm. Venereol. (2002) 82(1):7-12.
   PubMed Web of Science ®Google Scholar
• CHEN CS, WELLS J, CRAIG JE: Topical prostaglandin F(2alpha) analog induced poliosis. Am. J. Ophthalmol. (2004) 137(5):965-966.
   PubMed Web of Science ®Google Scholar
• FELDMAN RM: Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J. Ocul. Pharmacol. Ther. (2003) 19(1):23-35.
   PubMed Web of Science ®Google Scholar
• HIGGINBOTHAM EJ, SCHUMAN JS, GOLDBERG I et al.: One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch. Ophthalmol. (2002) 120(10):1286-1293.
   PubMed Web of Science ®Google Scholar
• CHIBA T, KASHIWAGI K, CHIBA N, TSUKAHARA S: Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br. J. Ophthalmol. (2006) 90(3):314-317.
   PubMed Web of Science ®Google Scholar
• WALTERS TR, DUBINER HB, CARPENTER SP, KHAN B, VANDENBURGH AM; BIMATOPROST CIRCADIAN IOP STUDY GROUP: 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv. Ophthalmol. (2004) 49(Suppl. 1):S26-S35.
   PubMed Web of Science ®Google Scholar
• FELLMAN RL, SULLIVAN EK, RATLIFF M et al.: Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology (2002) 109(5):998-1008.
   PubMed Web of Science ®Google Scholar
• COLEMAN AL, LERNER F, BERNSTEIN P, WHITCUP SM: A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology (2003) 110(12):2362-2368.
   PubMed Web of Science ®Google Scholar
• WATSON P, STJERNSCHANTZ; THE LATANOPROST STUDY GROUP: A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology (1996) 103(1):126-137.
   PubMed Web of Science ®Google Scholar
• KABACK M, GEANON J, KATZ G, RIPKIN D, PRZYDRYGA J; START STUDY GROUP: Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost. Curr. Med. Res. Opin. (2004) 20(9):1341-1345.
   PubMed Web of Science ®Google Scholar
• PRZYDRYGA JT, EGLOFF C; SWISS START STUDY GROUP: Intraocular pressure lowering efficacy of travoprost. Eur. J. Ophthalmol. (2004) 14(5):416-422.
   PubMed Web of Science ®Google Scholar
• HOLLÓ G, VARGHA P, KÓTHY P: Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication. Curr. Med. Res. Opin. (2005) 21(12):1943-1948.
   PubMed Web of Science ®Google Scholar
• BOURNIAS TE, LEE D, GROSS R, MATTOX C: Ocular hypotensive efficacy of bimatoprost when used as a replacement for latanoprost in the treatment of glaucoma and ocular hypertension. J. Ocul. Pharmacol. Ther. (2003) 19(3):193-203.
   PubMed Web of Science ®Google Scholar
• ABELSON MB, MROZ M, ROSNER SA, DIRKS MS, HIRABAYASHI D: Multicenter, open-label evaluation of hyperemia associated with use of bimatoprost in adults with open-angle glaucoma or ocular hypertension. Adv. Ther. (2003) 20(1):1-13.
   PubMed Web of Science ®Google Scholar
• BAYER A, WEILER W, OEVERHAUS U, SKROTZKI FE, STEWART WC; XPLORE OBSERVATION GROUP: Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. J. Ocul. Pharmacol. Ther. (2004) 20(6):470-478.
   PubMed Web of Science ®Google Scholar
• ALM A, WIDENGARD I: Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol. Scand. (2000) 78(1):71-76.
   PubMedGoogle Scholar
• QUINONES R, SEVERIN T, MUNDORF T: Efficacy of bimatoprost 0.03 percent in untreated glaucoma and ocular hypertension patients: results from a large community-based clinical trial. J. Ocul. Pharmacol. Ther. (2004) 20(2):115-122.
   PubMed Web of Science ®Google Scholar
• ZIMMERMAN TJ, STEWART WC; LATANOPROST AXIS STUDY GROUP: Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J. Ocul. Pharmacol. Ther. (2003) 19(5):405-415.
   PubMed Web of Science ®Google Scholar
• AGARWAL HC, GUPTA V, SIHOTA R: Effect of changing from concomitant timolol pilocarpine to bimatoprost monotherapy on ocular blood flow and IOP in primary chronic angle closure glaucoma. J. Ocul. Pharmacol. Ther. (2003) 19(2):105-112.
   PubMed Web of Science ®Google Scholar
• SHIN DH, MCCRACKEN MS, BENDEL RE et al.: The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy. Ophthalmology (1999) 106(2):386-390.
   PubMed Web of Science ®Google Scholar
• WATSON PG; LATANOPROST STUDY GROUP: Latanoprost. Two years’ experience of its use in the United Kingdom. Ophthalmology (1998) 105(1):82-87.
   PubMed Web of Science ®Google Scholar
• STEWART WC, KOLKER AE, STEWART JA, LEECH J, JACKSON AL: Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am. J. Ophthalmol. (2003) 135(3):314-320.
   PubMed Web of Science ®Google Scholar
• KONSTAS AG, KATSIMBRIS JM, LALLOS N, BOUKARAS GP, JENKINS JN, STEWART WC: Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology (2005) 112(2):262-266.
   PubMed Web of Science ®Google Scholar
• KONSTAS AG, BANYAI L, BLASK KD et al.: Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies. J. Ocul. Pharmacol. Ther. (2004) 20(5):375-382.
   PubMed Web of Science ®Google Scholar
• DIESTELHORST M, LARSSON LI; EUROPEAN-CANADIAN LATANOPROST FIXED COMBINATION STUDY GROUP: A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology (2006) 113(1):70-76.
   PubMed Web of Science ®Google Scholar
• HAMACHER T, SCHINZEL M, SCHOLZEL-KLATT A et al.: Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. Br. J. Ophthalmol. (2004) 88(10):1295-1298.
   PubMed Web of Science ®Google Scholar
• ORENGO-NANIA S, LANDRY T, VON TRESS M, SILVER LH, WEINER A, DAVIS AA; TRAVOPROST STUDY GROUP: Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am. J. Ophthalmol. (2001) 132(6):860-868.
   PubMed Web of Science ®Google Scholar
• BARNEBEY HS, ORENGO-NANIA S, FLOWERS BE et al.: The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am. J. Ophthalmol. (2005) 140(1):1-7.
   PubMed Web of Science ®Google Scholar
• SCHUMAN JS, KATZ GJ, LEWIS RA et al.: Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. (2005) 140(2):242-250.
   PubMed Web of Science ®Google Scholar
• HOLLÓ G, CHISELITA D, PETKOVA N et al.: The efficacy and safety of timolol maleate 0.5% versus brinzolamide 1% each given twice daily added to travoprost 0.004% in patients with ocular hypertension or primary open-angle glaucoma. Eur. J. Ophthalmol. (2006) (In Press).
   Google Scholar
• HOMMER A, KAPIK B, SHAMS N; THE UNOPROSTONE ADJUNCTIVE THERAPY STUDY GROUP: Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide. Br. J. Ophthalmol. (2003) 87(5):592-598.
   PubMed Web of Science ®Google Scholar
• NIGGEMANN B, WEINBAUER G, VOGEL F, KORTE R: A standardized approach for iris color determination. Int. J. Toxicol. (2003) 22(1):49-51.
   PubMed Web of Science ®Google Scholar
• STJERNSCHANTZ J, OCKLIND A, WENTZEL P, LAKE S, HU DN: Latanoprost-induced increase of tyrosinase transcription in iridial melanocytes. Acta Ophthalmol. Scand. (2000) 78(6):618-622.
   PubMedGoogle Scholar
• DRAGO F, MARINO A, LA MANNA C: α-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro. Exp. Eye Res. (1999) 68(1):85-90.
   PubMed Web of Science ®Google Scholar
• KASHIWAGI K, TSUKAMOTO K, SUZUKI M, TSUKAHARA S: Effects of isopropyl unoprostone and latanoprost on melanogenesis in mouse epidermal melanocytes. J. Glaucoma (2002) 11(1):57-64.
   PubMed Web of Science ®Google Scholar
• STJERNSCHANTZ JW, ALBERT DM, HU DN, DRAGO F, WISTRAND PJ: Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv. Ophthalmol. (2002) 47(Suppl. 1):S162-S175.
   PubMed Web of Science ®Google Scholar
• WENTZEL P, BERGH K, WALLIN O, NIEMELA P, STJERNSCHANTZ J: Transcription of prostanoid receptor genes and cyclooxygenase enzyme genes in cultivated human iridial melanocytes from eyes of different colours. Pigment Cell Res. (2003) 16(1):43-49.
   PubMedGoogle Scholar
• DUTKIEWICZ R, ALBERT DM, LEVIN LA: Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp. Eye Res. (2000) 70(5):563-569.
   PubMed Web of Science ®Google Scholar
• CHOU SY, CHOU CK, KUANG TM, HSU WM: Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes. Eye (2005) 19(7):784-787.
   PubMed Web of Science ®Google Scholar
• CHIBA T, KASHIWAGI K, CHIBA N et al.: Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study. Br. J. Ophthalmol. (2003) 87(8):956-959.
   PubMed Web of Science ®Google Scholar
• NORDMANN JP, MERTZ B, YANNOULIS NC, SCHWENNINGER C, KAPIK B, SHAMS N; UNOPROSTONE MONOTHERAPY STUDY GROUP-EU: A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am. J. Ophthalmol. (2002) 133(1):1-10.
   PubMed Web of Science ®Google Scholar
• JAMPEL HD, BACHARACH J, SHEU WP, WOHL LG, SOLISH AM, CHRISTIE W; LATANOPROST/UNOPROSTONE STUDY GROUP: Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am. J. Ophthalmol. (2002) 134(6):863-871.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, KITAZAWA Y: Iris-color change developed after topical isopropyl unoprostone treatment. J. Glaucoma (1997) 6(6):430-432.
   PubMed Web of Science ®Google Scholar
• MCCAREY BE, KAPIK BM, KANE FE; UNOPROSTONE MONOTHERAPY STUDY GROUP: Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%. Ophthalmology (2004) 111(8):1480-1488.
   PubMed Web of Science ®Google Scholar
• KOOK MS, LEE KÁ: Increased eyelid pigmentation associated with use of latanoprost. Am. J. Ophthalmol. (2000) 129(6):804-806.
   PubMed Web of Science ®Google Scholar
• HERNDON LW, ROBERT D WILLIAMS, WAND M, ASRANI S: Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am. J. Ophthalmol. (2003) 135(5):713-715.
   PubMed Web of Science ®Google Scholar
• KAPUR R, OSMANOVIC S, TOYRAN S, EDWARD DP: Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch. Ophthalmol. (2005) 123(11):1541-1546.
   PubMed Web of Science ®Google Scholar
• STEWART WC, STEWART JA, JENKINS JN, JACKSON AL: Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects. J. Glaucoma (2003) 12(6):475-479.
   PubMed Web of Science ®Google Scholar
• KOZOBOLIS VP, DETORAKIS ET, MASKALERIS G et al.: Corneal sensitivity changes following the instillation of latanoprost, bimatoprost, and travoprost eyedrops. Am. J. Ophthalmol. (2005) 139(4):742-743.
   PubMed Web of Science ®Google Scholar
• GUENOUN JM, BAUDOUIN C, RAT P, PAULY A, WARNET JM, BRIGNOLE-BAUDOUIN F: In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest. Ophthalmol. Vis. Sci. (2005) 46(7):2444-2450.
   PubMed Web of Science ®Google Scholar
• SHIMAZAKI J, HANADA K, YAGI Y et al.: Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone. Br. J. Ophthalmol. (2000) 84(11):1250-1254.
   PubMed Web of Science ®Google Scholar
• CELLINI M, CARAMAZZA R, BONSANTO D, BERNABINI B, CAMPOS EC: Prostaglandin analogs and blood–aqueous barrier integrity: a flare cell meter study. Ophthalmologica (2004) 218(5):312-317.
   PubMed Web of Science ®Google Scholar
• ARCIERI ES, SANTANA A, ROCHA FN, GUAPO GL, COSTA VP: Blood–aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch. Ophthalmol. (2005) 123(2):186-192.
   PubMed Web of Science ®Google Scholar
• SUOMINEN S, VALIMAKI J: Bilateral anterior uveitis associated with travoprost. Acta Ophthalmol. Scand. (2006) 84(2):275-276.
   PubMedGoogle Scholar
• WAND M, SHIELDS BM: Cystoid macular edema in the era of ocular hypotensive lipids. Am. J. Ophthalmol. (2002) 133(3):393-397.
   PubMed Web of Science ®Google Scholar
• WAND M, GAUDIO AR: Cystoid macular edema associated with ocular hypotensive lipids. Am. J. Ophthalmol. (2002) 133(3):403-405.
   PubMed Web of Science ®Google Scholar
• CARRILLO MM, NICOLELA MT: Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost. Am. J. Ophthalmol. (2004) 137(5):966-968.
   PubMed Web of Science ®Google Scholar
• VISHWANATH MR, CHARLES SJ: Does timolol LA enhance the disrupting effect of travoprost on the blood–aqueous barrier? Acta Ophthalmol. Scand. (2006) 84(3):441-442.
   PubMedGoogle Scholar
• KROLL DM, SCHUMAN JS: Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am. J. Ophthalmol. (2002) 133(3):401-403.
   PubMed Web of Science ®Google Scholar
• INAN UU, ERMIS SS, ORMAN A et al.: The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. J. Ocul. Pharmacol. Ther. (2004) 20(4):293-310.
   PubMed Web of Science ®Google Scholar
• HEDNER J, EVERTS B, MOLLER CS: Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation. Arch. Ophthalmol. (1999) 117(10):1305-1309.
   PubMed Web of Science ®Google Scholar
• WALDOCK A, SNAPE J, GRAHAM CM: Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br. J. Ophthalmol. (2000) 84(7):710-713.
   PubMed Web of Science ®Google Scholar
• STEWART WC, STEWART JA, CROCKETT S, KUBILUS C, BROWN A, SHAMS N: Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test. Acta Ophthalmol. Scand. (2002) 80(3):272-276.
   PubMedGoogle Scholar
• GUNAWARDENA KA, CRAME N, MERTZ B, SHAMS N: Safety of unoprostone isopropyl 0.15% ophthalmic solution in patients with mild to moderate asthma. Ophthalmologica (2003) 217(2):129-136.
   PubMed Web of Science ®Google Scholar
• COLEMAN AL, MOSAED S, KAMAL D: Medical therapy in pregnancy. J. Glaucoma (2005) 14(5):414-416.
   PubMed Web of Science ®Google Scholar
• JOHNSON SM, MARTINEZ M, FREEDMAN S: Management of glaucoma in pregnancy and lactation. Surv. Ophthalmol. (2001) 45(5):449-454.
   PubMed Web of Science ®Google Scholar
• VYSNIAUSKIENE I, ALLEMANN R, FLAMMER J, HAEFLIGER IO: Vasoactive responses of U46619, PGF2alpha, latanoprost, and travoprost in isolated porcine ciliary arteries. Invest. Ophthalmol. Vis. Sci. (2006) 47(1):295-298.
   PubMed Web of Science ®Google Scholar
• HOLLÓ G: Influence of intraocular pressure lowering on vascular supply. In: Glaucoma therapy. Shaarawy T, Flammer J (Eds), Martin Dunitz, London, UK (2004):143-161.
   Google Scholar
• AKARSU C, YILMAZ S, TANER P, ERGIN A: Effect of bimatoprost on ocular circulation in patients with open-angle glaucoma or ocular hypertension. Graefes Arch. Clin. Exp. Ophthalmol. (2004) 242(10):814-818.
   PubMed Web of Science ®Google Scholar
• SEONG GJ, LEE HK, HONG YJ: Effects of 0.005% latanoprost on optic nerve head and peripapillary retinal blood flow. Ophthalmologica (1999) 213(6):355-359.
   PubMed Web of Science ®Google Scholar
• BEANO F, ORGUL S, STUMPFIG D, GUGLETA K, FLAMMER J: An evaluation of the effect of unoprostone isopropyl 0.15% on ocular hemodynamics in normal-tension glaucoma patients. Graefes Arch. Clin. Exp. Ophthalmol. (2001) 239(2):81-86.
   PubMed Web of Science ®Google Scholar
• PEPLINSKI LS, ALBIANI SMITH K: Deepening of lid sulcus from topical bimatoprost therapy. Optom. Vis. Sci. (2004) 81(8):574-577.
   PubMed Web of Science ®Google Scholar
• KROHN J, HOVE VK: Iris cyst associated with topical administration of latanoprost. Am. J. Ophthalmol. (1999) 127(1):91-93.
   PubMed Web of Science ®Google Scholar
• BROWNING DJ, PERKINS SL, LARK KK: Iris cyst secondary to latanoprost mimicking iris melanoma. Am. J. Ophthalmol. (2003) 135(3):419-421.
   PubMed Web of Science ®Google Scholar
• HERNDON LW, ASRANI SG, WILLIAMS GH, CHALLA P, LEE PP: Paradoxical intraocular pressure elevation after combined therapy with latanoprost and bimatoprost. Arch. Ophthalmol. (2002) 120(6):847-849.
   PubMed Web of Science ®Google Scholar
• LEE YC: Abdominal cramp as an adverse effect of travoprost. Am. J. Ophthalmol. (2005) 139(1):202-203.
   PubMed Web of Science ®Google Scholar